All In Biotech

Drug Trial Radar · NCT07890714

A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]

A Phase 1/2, Multicenter, Master Protocol Trial to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) in Participants With Solid Tumors (TROPION-PanTumor04)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

268

Planned (sponsor's estimate)

Start

Oct 16, 2026

Primary completion

Sep 30, 2029

Study completion Jan 31, 2030

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.

Conditions

  • Urothelial Cancer
  • Non-small Cell Lung Cancer

Interventions

  • Dato-DXdDrug

    Dato-DXd will be administered as an IV infusion.

  • Enfortumab Vedotin (EV)Drug

    EV will be administered as IV infusion.

  • PembrolizumabDrug

    Pembrolizumab will be administered as an IV infusion.

  • OlomorasibDrug

    Olomorasib will be administered as oral capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: During Cycle 1 (cycle length = 21 days)
  2. Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2.9 years
  3. Phase 2: Objective Response Rate (ORR) as Assessed by InvestigatorTime frame: Up to approximately 2.9 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TCVGH (Taichung Veterans General Hospital)

    Taichung, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.